Key statistics
As of last trade Eledon Pharmaceuticals Inc (ELDN:NAQ) traded at 3.94, -28.97% below its 52-week high of 5.54, set on Nov 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.08 |
---|---|
High | 4.17 |
Low | 3.93 |
Bid | 3.93 |
Offer | 3.95 |
Previous close | 4.07 |
Average volume | 328.60k |
---|---|
Shares outstanding | 59.74m |
Free float | 59.71m |
P/E (TTM) | -- |
Market cap | 243.14m USD |
EPS (TTM) | -0.3861 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:41 GMT.
More ▼
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
- Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
- Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
- Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
- Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
- Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
- Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
More ▼